Daxor Expands Blood Volume Testing to High-Volume Ohio Cardiology Center
Event summary
- Daxor launched its BVA program at a high-volume cardiology facility in Southwest Ohio on April 8, 2026.
- The facility gains access to 24-hour turnaround on blood volume metrics via Daxor’s ezBVA Lab workflow.
- Daxor’s ‘lab-as-a-service’ model eliminates the need for onsite laboratory infrastructure.
- Michael Feldschuh, Daxor CEO, emphasizes the shift from subjective assessments to data-driven precision in heart failure care.
The big picture
Daxor’s expansion into Ohio aligns with the growing demand for precise, data-driven diagnostics in chronic disease management. The ‘lab-as-a-service’ model addresses capital investment hurdles, potentially accelerating adoption in value-based healthcare. The move underscores a broader industry shift toward reducing systemic healthcare costs through targeted, efficient diagnostics.
What we're watching
- Adoption Pace
- How quickly Daxor can scale its ‘lab-as-a-service’ model across other high-volume cardiology centers.
- Reimbursement Dynamics
- Whether existing reimbursement codes will sustain broader clinical adoption of BVA technology.
- Competitive Response
- The likelihood of competitors developing similar lab-as-a-service models for blood volume testing.
Related topics